Effect of Inhibition of the Lysophosphatidic Acid Receptor 1 on Metastasis and Metastatic Dormancy in Breast Cancer

Jean-Claude A. Marshall, Joshua W. Collins, Joji Nakayama, Christine E. Horak, David J. Liewehr, Seth M. Steinberg, Mary Albaugh, Fernando Vidal-Vanaclocha, Diane Palmieri, Maryse Barbier, Maximilien Murone, Patricia S. Steeg

Manuscript received August 10, 2011; revised June 13, 2012; accepted June 18, 2012.

Correspondence to: Patricia S. Steeg, PhD, Bldg 37, Rm 1122, National Institutes of Health, Bethesda, MD 20892 (e-mail: steegp@mail.nih.gov).

Background

Previous studies identified the human nonmetastatic gene 23 (NME1, hereafter Nm23-H1) as the first metastasis suppressor gene. An inverse relationship between Nm23-H1 and expression of lysophosphatidic acid receptor 1 gene (LPA1, also known as EDG2 or hereafter LPA1) has also been reported. However, the effects of LPA1 inhibition on primary tumor size, metastasis, and metastatic dormancy have not been investigated.

Methods

The LPA1 inhibitor Debio-0719 or LPA1 short hairpinned RNA (shRNA) was used. Primary tumor size and metastasis were investigated using the 4T1 spontaneous metastasis mouse model and the MDA-MB-231T experimental metastasis mouse model (n = 13 mice per group). Proliferation and p38 intracellular signaling in tumors and cell lines were determined by immunohistochemistry and western blot to investigate the effects of LPA1 inhibition on metastatic dormancy. An analysis of variance-based two-tailed t test was used to determine a statistically significant difference between treatment groups.

Results

In the 4T1 spontaneous metastasis mouse model, Debio-0719 inhibited the metastasis of 4T1 cells to the liver (mean = 25.2 liver metastases per histologic section for vehicle-treated mice vs 6.8 for Debio-0719-treated mice, 73.0% reduction, P < .001) and lungs (mean = 6.37 lesions per histologic section for vehicle-treated mice vs 0.73 for Debio-0719-treated mice, 88.5% reduction, P < .001), with no effect on primary tumor size. Similar results were observed using the MDA-MB-231T experimental pulmonary metastasis mouse model. LPA1 shRNA also inhibited metastasis but did not affect primary tumor size. In 4T1 metastases, but not primary tumors, expression of the proliferative markers Ki67 and pErk was reduced by Debio-0719, and phosphorylation of the p38 stress kinase was increased, indicative of metastatic dormancy.

Conclusion

The data identify Debio-0719 as a drug candidate with metastasis suppressor activity, inducing dormancy at secondary tumor sites.

J Natl Cancer Inst 2012;104:1306–1319
Methods

Cell Lines
Murine mammary carcinoma 4T1 luciferase-labeled cells, a gift from Dr Gary Sahagian (Tufts University, Boston, MA), were cultured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen, Frederick, MD) supplemented with 10% fetal bovine serum. A subline of human MDA-MB-231 cells, designated MDA-MB-231T (50), was generously provided by Dr Zach Howard (Laboratory of Immunoregulation, National Cancer Institute, Bethesda, MD) and was maintained in DMEM supplemented with 10% fetal bovine serum. The MDA-MB-231T cell line was used for its reliable in vivo experimental metastatic potential.

Clones of 4T1 cells expressing flag-tagged Nm23-H1, flag-tagged mouse Nm23 (Nm23-M1), or empty pcDNA3 vector (Invitrogen) were created. The cDNAs were inserted into the BamH1 site in the multiple cloning site of pcDNA3 (Invitrogen), and confirmed by DNA sequencing performed by the National Cancer Institute Core Services (Bethesda, MD). The plasmids were transfected into 4T1 cells using Lipofectamine (Invitrogen, Valencia, CA) by the manufacturer’s recommended protocol. Forty-eight hours after transfection, cells were cultured in DMEM containing 10% fetal bovine serum, 600 µg/mL G418 (Invitrogen), and the clonal cell lines were subsequently isolated and cultured.

LPA1 Inhibitors
Debio-0719 was provided by Debiopharm S.A. (Lausanne, Switzerland) and was stored in powder form in the dark at room temperature. For all experiments, Debio-0719 was dissolved into sterile phosphate-buffered saline, and phosphate-buffered saline served as the vehicle control for in vitro and in vivo experiments.

For the in vitro assays, Debio-0719 was used at a concentration of 60 nM, which was the half maximal inhibitory concentration for antagonistic activity (IC50) (data not shown).

LPA1 knockdown was achieved using two validated lentiviral shRNA constructs from Sigma-Aldrich (St. Louis, MO) as per the manufacturer’s recommendations (catalog no. shclnv-nm 010336). Scrambled shRNA constructs were used as a negative control (Sigma-Aldrich).

Western Blots
Whole cell lysates were prepared, and protein concentrations were determined using the methods given in the Supplementary Materials (available online). After proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes, the membranes were probed with antibodies and then visualized on X-ray film (Supplementary Methods and Supplementary Table 1, available online).

In Vitro Functional Assays
Cell proliferation was measured by 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Supplementary Methods, available online). Anchorage-independent growth was also assessed (Supplementary Methods, available online). For both the cell proliferation and anchorage-independent growth assays, five independent experiments were performed.

Migration assays were performed as described [(26) and Supplementary Methods, available online]. Briefly, 4T1 or MDA-MB-231T cells were incubated in the top compartments of Boyden chambers in the presence of vehicle control or varying concentrations of Debio-0719. The number of cells that had migrated through the chamber was quantified. Three independent experiments were performed, each in triplicate.

Adhesion assays were performed using the CultureCoat Adhesion Protein Array Kit ( Trevigen, Gaithersburg, MD) as per the manufacturer’s recommended protocol (Supplementary Methods, available online).

In Vivo Studies
All mouse experiments were performed under an approved National Cancer Institute Animal Use Agreement. Female six-week-old Balb/c or athymic NRC nu/nu mice were used.

Spontaneous Metastasis Mouse Model. For the spontaneous metastasis experiments, 4T1 cells (parental or modified by stable transfection with one of two LPA1 shRNAs, a scrambled shRNA, Nm23-H1 constructs, or a vector control construct) were injected into the mammary fat pads of female Balb/c mice (n = 10 mice per group) (Supplementary Methods, available online). The primary tumors were measured twice weekly until resection, which occurred on days 10 or 14, depending on the experiment. After 8–11 weeks, depending on the experiment, all lymph nodes, lungs, livers, and any other organ suspected of harboring a metastasis were collected for histologic analysis. The schedule of randomization to vehicle (phosphate-buffered saline) or Debio-0719 (15 mg/kg given subcutaneously twice daily) varied by experiment (Supplementary Methods, available online). Drug treatment started on day 2 postinjection of cells for efficacy experiments and on day 15 postinjection of cells for adjuvant experiments.

Experimental Pulmonary Metastasis Mouse Model. To investigate the effect of LPA1 inhibition on metastasis of human breast cancer cells in vivo, an experimental pulmonary metastasis study was conducted. Athymic NRC nu/nu mice were injected with 5 × 10^5 MDA-MB-231T human breast cancer cells via the tail vein [(50) and Supplementary Methods, available online]. On the day following injection, mice were randomized into three groups containing 13 mice each. The mice were assigned to one of the following treatment groups: vehicle, 15 mg/kg Debio-0719 given twice daily subcutaneously or 15 mg/kg Debio-0719 given twice daily subcutaneously for 35 days followed by administration of vehicle control for the remainder of the study. Mice were killed at day 42 by being placed in a carbon dioxide chamber, and the lungs were collected and fixed in Bouins’ solution (50). Surface metastatic lesions were counted on all lungs using a magnifying glass, blinded to the treatment group, before the lungs were embedded in paraffin for histological analysis (Supplementary Methods, available online).

To investigate the effect of LPA1 inhibition on primary tumor growth, 5 × 10^5 MDA-MB-231T human breast cancer cells were implanted into the mammary fat pads of athymic NRC nu/nu mice. The day following implantation, mice were randomized into two groups of five mice each and treated with vehicle control or 15 mg/kg Debio-0719 given twice daily subcutaneously. The growth of
the primary tumor in the mammary fat pad was measured twice weekly by caliper until day 32, at which time they were killed in a carbon dioxide chamber. The tumors were then excised, and 5-μm sections were stained with hematoxylin and eosin and analyzed by a pathologist. Tissues were also used for immunofluorescence or immunohistochemical staining (51) for expression of different proteins (Supplementary Methods, available online).

**Primary Organ–Conditioned Media**
Conditioned medium collected from primary cultures of mammary fat pads, livers, and lungs from Balb/c mice (Supplementary Methods, available online) was assayed for soluble cytokine expression using cytokine antibody arrays per the manufacturer’s protocol (Supplementary Methods, available online).

To model activation of Erk and p38 in vitro, 4T1 cells that were plated on type I collagen-coated 35-mm dishes were cultured in the presence of vehicle or Debio-0719 for 48 hours and then serum-starved overnight. To study activation of phosphorylated proteins (Erk and p38) or total protein levels (MKK4, MKK6, and p27), cells were then stimulated with 20% (v/v) conditioned medium from mammary fat pad, livers, or lungs before lysis and western blot analysis.

**Statistical Analysis**
A variety of analyses of variances (ANOVA) were performed on the raw or transformed data. Please see the Supplementary Methods (available online) for details. A nonparametric Wilcoxon rank sum test was used to compare distributions if the data were not normally distributed and/or the sample sizes were less than 10 mice per group. Dunnett method was used to adjust the P values for pair-wise comparisons between a control and other treatments. Otherwise, Holm method was used to adjust pair-wise P values. Because of the multiple tests, we consider a P of .01 as the upper limit of what may be interpreted as being statistically significant; a strong trend was indicated if P was greater than .01 but less than .05, and any P greater than .05 was not statistically significant. Diffuse metastasis counts, in which metastases filled the liver and quantitative counts were not feasible, were excluded from the statistical analysis because they could potentially introduce bias. Actuarial analyses were performed on the survival data using the Kaplan–Meier method, and curves were compared using the log-rank test. Survival times were censored if the mouse was alive at the time of the last follow-up. All P values were two-sided.

**Results**

**Nm23-H1 Function in a 4T1 Metastasis Model System**
Luciferase-expressing 4T1 murine mammary carcinoma cells produce primary orthotopic mammary tumors and widespread spontaneous metastases in immunocompetent mice (52). qRT-PCR of 4T1 cells demonstrated expression of LPA family receptors LPA1, LPA2, LPA6, and related GPR87, with minor expression of LPA3, LPA4, LPA5, and related P2Y10 (data not shown). To determine the effect of Nm23 overexpression, 4T1 cells were transfected with a vector construct (VC), or the human (H1) or murine (M1) homologs of Nm23 (Figure 1, A). Mammary fat pad primary tumor sizes from clonal lines at the time of resection were comparable between Nm23 and vector transfectants (Figure 1, B). Overexpression of Nm23 reduced the number of metastases to the liver by 62.4%--69.7% and lungs by 85.1%--94.6% (all P < .05 compared with either 4T1 parental or vector controls) (Figure 1, C and D). Expression of LPA1 was reduced in 4T1 cells and primary tumors overexpressing Nm23 (Figure 1, E and F).

The molecular structure of Debio-0719, an LPA1 inhibitor, is shown (Figure 2, A). The half maximal inhibitory concentration for antagonist activity of Debio-0719 for LPA1 was 60 nM, with less potent inhibition of LPA3 at 660 nM and LPA2 at 2 μM (data not shown). In vitro, Debio-0719 exerted little antiproliferative effect on 4T1 cells (data not shown) but inhibited their motility (Supplementary Figure 1, available online).

**4T1 Spontaneous Metastasis Experiments Using Debio-0719**
Figure 2, B outlines the first set of 4T1 experiments to test the hypothesis that a LPA1 inhibitor would act as a metastasis suppressor. Mice were injected with 4T1 cells in the mammary fat pads on day 0 and then randomized to vehicle or Debio-0719 beginning 2 days postinjection. Mice injected with an Nm23-M1a transfectant of 4T1 cells and treated with vehicle served as a positive control for metastasis suppressor activity. No antitumor effect of Debio-0719 was observed in the primary tumors at the time of resection on day 10 postinjection (P = .98) (Figure 2, C and D). Therefore, this compound would not normally be further studied for drug development purposes.

Imaging experiments to determine 4T1 metastatic burden, conducted on day 70 postinjection, showed that Debio-0719 had a metastasis-suppressive effect (Figure 2, D). Enlarged lymph nodes were apparent at the time of necropsy in 22 (55.0%) of 40 vehicle-treated mice vs 6 (15.0%) of 40 Debio-0719-treated mice and 6 (15.0%) of 40 mice with 4T1 Nm23-M1a tumors in which metastasis was suppressed. A mean of 25.2 liver metastases per histologic section was observed for vehicle-treated mice vs 6.8 for Debio-0719-treated mice (73.0% reduction, median difference = 18.4 metastases per liver, 95% confidence interval [CI] = 12.7 to 24.2, P < .001) and 5.3 for mice injected with 4T1 Nm23-M1a cells (79.0% reduction, median difference = 19.9 metastases per liver, 95% CI = 16.2 to 23.7, P < .001) (Figure 2, E). In addition, 6 (15.0%) of 40 vehicle-treated mice exhibited diffuse sinusoidal liver metastasis that could not be quantified (Supplementary Figure 2, available online) vs 3 (7.5%) of 40 mice treated with Debio-0719. The mice with diffuse metastases were not included in the statistical analysis and therefore represent a potential bias because they would all reflect large values. A similar trend was observed in lung metastases when a mean of 6.37 lesions per histologic section was observed for vehicle-treated mice vs 0.73 lesions per section for Debio-0719-treated mice (88.5% reduction, median difference = 5.64 metastases per lung, 95% CI = 4.75 to 6.53, P < .001) and a 90.1% decline to 0.63 lesions per section for mice injected with 4T1 Nm23-M1a, vehicle-treated cells (median difference = 5.74 metastases per lung, 95% CI = 4.87 to 6.61, P < .001) (Figure 2, E and Supplementary Figure 2, available online). The number of lung metastases produced by 4T1 Nm23-M1a transfectants was not statistically significantly different from those produced by 4T1 cells treated with Debio-0719 (P = .72). Debio-0719
Figure 1. Effects of nonmetastatic gene 23 (Nm23) suppression on metastasis and lysophosphatidic acid receptor 1 (LPA1) expression in the 4T1 spontaneous metastasis mouse model. A) Nm23 expression in independent clones of 4T1 murine mammary cells transfected with either a vector construct (VC1 and VC2), flag-tagged Nm23-H1 (human ortholog, H1Flg construct; H1a and H1b clones) or flag-tagged Nm23-M1 (mouse ortholog, M1Flg construct; M1a and M1b clones) was confirmed by western blot. Tubulin was used as the loading control. B) The size of primary tumors in the mammary fat pad formed by the parental 4T1 cell line and each clone on day 10 postinjection (n = 20 Balb/c mice per group) was measured. The least-squares mean tumor volume and 95% confidence intervals (whisker bars) are shown. The mean number of metastases in the (C) liver and (D) lungs (bar) was determined at day 70 after orthotopic injection. Metastases were quantified from step sections of tissues stained with hematoxylin and eosin. The combined results from two independent experiments are presented. E) Western blot analysis of LPA1 protein expression in the transfected clones is shown. Tubulin was used as the loading control. F) The primary tumors from mice injected with the VC1 and M1a clones sectioned and underwent immunofluorescence staining for LPA1 protein (green). Tumor nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI, blue). Scale bar = 220 µm.
Figure 2. The effect of treatment with Debio-0719 on metastasis suppression in the 4T1 spontaneous metastasis mouse model. A) The chemical structure of Debio-0719 is depicted. B) The experimental design is outlined. 4T1 cells were injected into the mammary fat pads of Balb/c syngeneic mice on day 0. On day 2, mice were randomized to receive vehicle or 15 mg/kg Debio-0719 given subcutaneously twice daily. Primary tumors were resected on day 10 postinjection. Mice were killed on day 70 postinjection, and the metastases were quantified. Combined data from two independent experiments are shown (n = 40 mice per group). A third experimental group of 4T1 cells transfected with mouse nonmetastatic gene 23 (Nm23-M1; hereafter M1a cells) was treated with vehicle (n = 40) as a positive control. C) The least-squares mean of the primary tumor size and corresponding 95% confidence intervals (whisker bars) at day 10 postinjection are given. D) Representative images of primary tumors on day 10 postinjection (left panels) and metastatic burden on day 70 postinjection (right panels) taken using a Xenogen In Vivo Imaging System (Caliper Life Sciences, Hopkinton, MA) are shown. Please see the color scale to the right of each image, which shows the intensity range of photon flux per second from the 4T1 cells. E) The mean number of metastases in step sections of liver and lungs and 95% confidence intervals (whisker bars) are shown. *P < .001 compared with the vehicle control-treated mice and was determined by a two-sided t test done with transformed data. The differences between the mean number of metastases to the liver for Debio-0719 and M1a vehicle-treated groups were not statistically significant. Similar results were seen for metastases to the lungs.

was reliably detected in serum, and the weight measurements of mice indicated no overt toxic effects (Supplementary Figure 3, available online).

To confirm that LPA1 inhibition was responsible for metastatic suppression, LPA1 expression in 4T1 cells was stably knocked down using shRNAs (Figure 3, A). Knockdown of LPA1 expression by
Figure 3. Effect of treatment with Debio-0719 on metastasis in the 4T1 spontaneous metastasis mouse model. A) 4T1 cells were transfected with a scramble control short hairpinned RNA (shRNA) or one of two independent shRNAs targeting lysophosphatidic acid receptor 1 (LPA1; clone 1 and clone 2). Cell lysates were collected and underwent western blot for LPA1. Tubulin was used as the loading control. B–D) Syngeneic Balb/c mice were injected with 4T1 cells into the mammary fat pad on day 0, and primary tumors were resected on day 14 postinjection. The mice were randomized to vehicle (n = 10) or 15 mg/kg of Debio-0719 subcutaneously administered twice daily (n = 10) beginning either on days 2 or 15 postinjection. The 4T1 LPA1 shRNA clone 1 was also injected and treated with vehicle as a positive control (n = 10). B) Primary tumor size was measured, and the least-squares mean and 95% confidence intervals (whisker bars) are shown. C–D) The mean number of metastases (bar) in the liver and lungs per histologic section on day 56 postinjection was determined.

Table 1. Effect of LPA1 knockdown in a 4T1 mammary carcinoma spontaneous metastasis model

<table>
<thead>
<tr>
<th>Response</th>
<th>Scrambled shRNA</th>
<th>LPA1 shRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vehicle (n = 10)</td>
<td>Debio-079 (n = 9)</td>
</tr>
<tr>
<td>Least-squares mean tumor size, mm³ (95% CI)</td>
<td>400 (290 to 510)</td>
<td>336 (226 to 446)</td>
</tr>
<tr>
<td>No. of mice with diffuse liver metastases</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Median no. of liver metastases per section (95% CI)</td>
<td>24 (19 to 101)</td>
<td>6.25 (2.5 to 13)</td>
</tr>
<tr>
<td>% relative to control</td>
<td>100</td>
<td>26.0</td>
</tr>
<tr>
<td>Median no. of lung metastases per section (95% CI)</td>
<td>2.0 (1.5 to 3.5)</td>
<td>0.5 (0 to 1.5)</td>
</tr>
<tr>
<td>% relative to control</td>
<td>100</td>
<td>25.0</td>
</tr>
</tbody>
</table>

* 4T1 murine mammary carcinoma cells were transfected with a scrambled or LPA1 shRNA. Transfectants were injected into the mammary fat pads of syngeneic Balb/c mice and after 2 days, mice were randomized to vehicle (phosphate buffered saline) or 15 mg/kg Debio-0719 administered subcutaneously twice daily. The size of the primary tumor was measured using calipers on day 14 postinjection, and the primary tumor was resected. The metastases were quantified at day 56 postinjection. CI = confidence interval; LPA1 = lysophosphatidic acid receptor 1; shRNA = short hairpinned RNA.
shRNA decreased the in vitro motility of 4T1 cells; Debio-0719 did not exhibit an additive or synergistic effect when combined with shRNA to LPA1 (Supplementary Figure 4, available online). An LPA1 shRNA and a scrambled shRNA 4T1 clone were injected into the mammary fat pads of syngeneic mice; on day 2 postinjection, mice in each treatment group were randomized to vehicle or Debio-0719 treatment (Table 1). Mean primary tumor sizes on day 14, just before surgical removal, were similar ($P = .86$). LPA1 shRNA knockdown reduced liver metastases by 43.7%, from 24 to 13.5 metastases per histologic section (median difference = 10.5 metastases per liver, 95% CI = 4.0 to 22, $P = .01$), and lung metastases by 50.0%, from 2.0 to 1.0 (median difference = 1.0 metastases per lung, 95% CI = 0.5 to 3.5, $P = .004$). Thus, LPA1 inhibition mediated metastasis suppression. LPA1 shRNA knockdown showed similar inhibition of lung metastases, but it was less effective for liver metastases compared with Debio-0719 treatment of mice harboring scrambled shRNA 4T1 cells. Immunofluorescence staining of LPA1 in shRNA 4T1 cell liver metastases demonstrated some reexpression of the target gene in vivo (data not shown), a potential reason for the incomplete effect of LPA1 shRNA in inhibiting metastasis.

Finally, we determined whether the metastasis-suppressive effect of Debio-0719 was independent of treating the primary tumor. An experiment similar in design to that shown in Figure 2, B was conducted, except that primary tumors were removed on day 15 postinjection, and mice were subsequently randomized to vehicle or Debio-0719. Primary tumor size among the randomized groups was comparable ($P = .07$) (Figure 3, B). Treatment with Debio-0719 beginning on day 15 postinjection reduced the number of liver metastases per histologic section at necropsy on day 56 postinjection by 51.6% from 27.5 to 13.3 (median difference = 14.2 metastases per liver, 95% CI = 3.5 to 40.5, $P = .01$) (Figure 3, C) and the number of lung metastases per section by 75.0% from 3.0 to 0.75 (median difference = 2.3 metastases per lung, 95% CI = 0 to 3.5, $P = .11$) (Figure 3, D). These metastatic burdens were not statistically significantly different from either Debio-0719 administered beginning on day 2 postinjection or 4T1 cells expressing an LPA1 shRNA and treated with vehicle ($P = .61$ and .41, respectively). Taken together, LPA1 inhibition, by shRNA or Debio-0719, has antimetastatic function in the 4T1 model system.

**LPA1-Mediated Metastasis Suppression Exhibits Hallmarks of Dormancy**

Histologic sections of primary and metastatic 4T1 tissues were analyzed for proliferative and apoptotic markers to determine the mechanism of site-specific responsiveness to Debio-0719. The Ki67 labeling of primary tumors from mice treated with vehicle or Debio-0719 was comparable ($P = .86$) (Figure 4, A). In contrast, in vehicle-treated liver metastases, 15.3% of tumor cells were Ki67 positive and declined by 64.7% to 5.4% in the Debio-0719-treated lesions (median difference = 9.9% of cells positive, 95% CI = 4.1%
to 15.6%, \( P = .005 \) (Figure 4, B). Similar trends were observed in 4T1 lung metastases (data not shown). No detectable cleaved caspase 3 was observed at any site (data not shown). Thus, LPA1 pathway interruption inhibited tumor proliferation in a site-specific manner, suggesting that metastatic dormancy was induced.

Metastatic dormancy is widespread in breast, prostate, and other cancers, although the molecular basis is not completely known. Dormancy has been proposed to result from the reciprocal down-regulation of the proliferative Erk Map kinase pathway and upregulation of the p38 stress Map kinase pathway (53,54). The percentage of pErk- and phospho-p38-positive tumor cells in primary tumors from vehicle- and Debio-0719-treated mice were comparable (\( P = .55 \) for both pErk and phospho-p38) (Figure 5, A). In contrast, pErk was consistently downregulated in Debio-0719-treated liver metastases (Figure 5, B), decreasing 86.4%, from 51.5% positivity in the vehicle group to 7.0% in the Debio-0719 group (mean difference = 44.5% of cells positive, 95% CI = 35.6% to 53.4%, \( P = .007 \)). Phospho-p38 positivity showed the opposite pattern in liver metastases, increasing from 1.6% of tumor cells in the vehicle group to 50.6% of Debio-0719-treated tumor cells (mean difference = 49.0% of cells positive, 95% CI = 38.5% to 59.9%, \( P = .002 \)). Similar trends were observed in 4T1 lung metastases (data not shown). The data support the hypothesis that LPA1 inhibition induced metastatic dormancy.

**Debio-0719 in a MDA-MB-231T Pulmonary Metastasis Model**

To confirm the metastasis suppressor function of Debio-0719, the low Nm23-H1–expressing, hormone receptor–negative MDA-MB-231T human breast carcinoma cell line (50) was injected either in the mammary fat pad to produce primary tumors or in the tail vein to produce experimental lung metastases; mice were randomized to vehicle or Debio-0719 beginning on day 2 postinjection. Primary tumor size 28 days postinjection was not statistically significantly decreased by Debio-0719 (\( P = .98 \)) (Figure 6, A). Within the 42-day time frame of the experimental metastasis assay, 13 (100.0%) of 13 vehicle-treated mice succumbed to breathing difficulties vs 1 (7.7%) of 13 mice receiving continuous Debio-0719 (Figure 6, B, green vs red). Representative lungs from the vehicle and continuous Debio-0719 treatment groups, shown on Figure 6, C, indicate drug-induced metastasis suppression. The median number of surface lung metastases per mouse was 166 in the vehicle group and decreased 77.1% to 38 with continuous Debio-0719 treatment (median difference = 128 metastases per lung, 95% CI = 83 to 170, \( P < .001 \)) (Figure 6, D). A median of seven large metastases (>5 mm in the largest dimension) was present in the vehicle group (Figure 6, E) and decreased 100.0% to a median of 0 in the Debio-0719 group (median difference = 7 metastases per lung, 95% CI = 3 to 8, \( P < .001 \)), indicating suppression of both metastasis number and size.

To determine if continuous Debio-0719 was required for metastasis suppression, a third treatment group was treated with Debio-0719 for 35 days, at which time 14 (100.0%) of 14 mice were alive; thereafter, mice were switched to vehicle. Survival progressively decreased because mice with labored breathing were killed, and pulmonary metastases were evident at necropsy, indicating that suppression of metastasis was reversible (\( P < .05 \) for all three groups) (Figure 6, B).

The Ki67 proliferative status of MDA-MB-231T experimental lung metastases also suggested induction of dormancy by Debio-0719, which was reversed when treatment was stopped (Supplementary Figure 5, available online). For MDA-MB-231T lung metastases, which harbor Ras and B-Raf mutations (55), constitutively activated pErk was observed under all conditions. However, Debio-0719
Figure 6. Effect of Debio-0719 on primary tumor size and experimental pulmonary metastasis in the MDA-MB-231T mouse model. 

A) MDA-MB-231T cells were injected into the mammary fat pads of athymic NRC nu/nu mice. The day following implantation, mice were randomized into two groups (n = 5) and administered either vehicle control or 15 mg/kg Debio-0719 given subcutaneously twice daily. Mice were killed on day 32. The median volume of the primary tumors on day 32 is depicted by the bars. 

B–D) MDA-MB-231T cells were injected into the tail veins of athymic NRC nu/nu mice on day 0. On the following day, the mice were randomized into groups (n = 13 or 14) and treated with vehicle, 15 mg/kg Debio-0719 subcutaneously twice daily, or 15 mg/kg Debio-0719 subcutaneously twice daily for 35 days postinjection and then administered vehicle thereafter. Mice were killed when breathing distress was observed. Kaplan–Meier survival curves are shown, and the number of mice at risk is given in the table below. Censored data is indicated by a +. C) Representative pictures of the lungs harvested from the mice in each treatment group are shown. The metastases are indicated by the lighter nodules that are apparent on the surface of the lungs. D) The dot plot shows the total number of metastatic nodules on the surface of the lungs from mice in each group. Any nodule larger than 5 mm in size was classified separately as a large metastasis, and these data are shown separately in (E). The median of each group is indicated by the bar. F) Lung tissues from mice shown in panels (B–D) underwent immunohistochemical staining for phospho-p38. Scale bar = 220 µm.
Figure 7. Effect of lysophosphatidic acid receptor 1 (LPA1) inhibition on p38 activation in vitro. A) 4T1 cells were plated on plastic or type I collagen-coated cell culture plates, were serum-starved overnight, and then stimulated with 5 µM lysophosphatidic acid (LPA) for 0, 1, 5, or 10 minutes. Cell lysates were prepared, and western blotting for total and phosphorylated proteins, including focal adhesion kinase (FAK), phospholipase Cβ (PLCβ), Erk1/2, p38, and β-actin (loading control), was done. B) 4T1 cells were plated on type I collagen-coated plates, serum-starved overnight, and treated with vehicle control or 60 nM Debio-0719. Cells were then stimulated with LPA for 0, 1, 5, or 10 minutes. Cell lysates were prepared, and western blotting for total and phosphorylated proteins, including FAK, PLCβ, Erk1/2, p38, and tubulin (loading control), was done. C) 4T1 cells were cultured on type I collagen-coated culture plates in the presence of 60 nM Debio-0719 and then serum-starved and stimulated with 20% (v/v) conditioned medium (CM) from liver, lungs, or mammary fat pads (MFP) for 10 or 60 minutes. Phosphorylated and total Erk and p38 protein levels were determined by western blot. D) 4T1 cells expressing LPA1 short hairpinned (shRNA) or a scrambled control shRNA were cultured on type I collagen-coated plates in the presence of 60 nM Debio-0719 or vehicle control and then serum-starved and stimulated with 20% (v/v) conditioned medium (CM) from liver, serum-free medium, or LPA only for 1 hour. Phosphorylated and total Erk and p38 protein levels were determined by western blot. Tubulin served as the loading control. E) 4T1 cells were cultured as described in panel (C), but lysates were prepared after 10 minutes of stimulation with CM, serum-free medium, and probed for total and phosphorylated MAP kinases. The images shown for (A–E) are representative of three independent experiments. F) Immunofluorescent images of MKK4 expression (green) in primary tumors or liver metastases (white dashed line) from either vehicle- or Debio-0719-treated primary tumor and liver tissues from mice used in the experiments described in Figure 2, B–E. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, blue). Scale bar = 220 µm.
elevated phospho-p38 in pulmonary metastases (Figure 6, F). In conclusion, the Debio-0719 compound suppressed metastasis in two model systems, with p38 activation a consistent hallmark.

**Contributors to Increased p38 Signaling in Metastatic Dormancy**

It is clear that metastatic dormancy in our model systems results from signaling that is distinct between the primary tumor and the distant metastases, as well as between normal conditions and LPA1 inhibition. LPA1 interacts with G-protein-coupled receptors to signal via multiple downstream pathways conferring tumor motility and invasion (56–62) as well as other phenotypes. When 4T1 cells were cultured with serum on plastic, treatment with LPA activated focal adhesion kinase and phospholipase Cβ (PLCβ) signaling, typical of motility and invasion, as well as Erk (Thr 202/ Tyr 204); no effect on p38 activation was observed (Figure 7, A). Histologic analysis indicated that 4T1 cells, in metastasizing to the liver, migrated from the portal venules of the liver past the basement membrane to the perivascular space, which is enriched for type I collagen (Supplementary Figure 6, A, available online); similar observations were made in the lung. In agreement with this observation, 4T1 cells adhered preferentially to type I collagen (Supplementary Figure 6, B, available online). When 4T1 cells were cultured with serum on type I collagen, the resulting signaling pattern recapitulated those observed in vivo to show LPA activation of Erk and diminution of phospho-p38 (Figure 7, A), which was inhibited by Debio-0719 treatment (Figure 7, B).

In examining the primary vs metastatic sites, we hypothesized that soluble factors present in the mammary fat pad vs liver and lung microenvironments may contribute to differential signaling patterns. Conditioned medium was prepared from freshly isolated primary cultures of dissected mouse mammary fat pads, lung fibroblasts, and parenchymal and nonparenchymal liver cells. Using cytokine arrays, 29 cytokines were overexpressed in conditioned media prepared from the lung and liver compared with conditioned medium from the mammary fat pad (Supplementary Figure 7, available online). The role of these conditioned media in metastatic dormancy signaling was investigated by culturing 4T1 cells on type I collagen, in the presence of various conditioned media (Figure 7, C). Erk was activated in 4T1 cells by lung and nonparenchymal liver–conditioned media to a greater degree than mammary fat pad–conditioned medium; activation was inhibited by Debio-0719 to recapitulate the observed in vivo expression trends. For p38, activation was stimulated by Debio-0719 over a longer time course, to a greater degree in the presence of liver and lung–conditioned media than with mammary fat pad–conditioned medium. These expression patterns were not observed when tumor cells were plated on plastic or type IV collagen (data not shown). Similar trends were observed using scrambled vs LPA1 shRNA knockdown 4T1 cells (Figure 7, D). Thus, in vitro culture of 4T1 cells on type I collagen in the presence of organ–conditioned medium modeled aspects of the in vivo metastasis data.

We further hypothesized that inhibition of LPA1 signaling specifically promoted p38 activation, regardless of the initiating stimulus. The p38 stress Map kinase is activated by Map2Ks (MKK3, MKK6, MKK4, and MKK7 can activate p38 or Jnk kinase) and Map3Ks (MKKs, TAK, and others) (63). When cultured on type I collagen, 4T1 cells expressed increased levels of total MKKK1, MKK3, and MKK4 in response to Debio-0719, regardless of the presence or type of conditioned medium (Figure 7, E). In agreement with these data, MKK4 expression was upregulated in liver metastases of Debio-0719 treated mice (Figure 7, F). Of the phospho-p38 MAP2Ks, MKK3 showed the highest levels of induction of total protein in response to LPA1 inhibition, and it signals directly to p38. One of the known targets of p38 is the cell cycle inhibitor p27 (64,65). In agreement with the p38 activation data, Debio-0719 enhanced p27 expression in vitro and in vivo (Figure 7, E and Supplementary Figure 8, available online). Collectively, the data suggest that the hyperactivation of p38 seen in metastatic dormancy may result from an abundance of stimulants in the metastatic microenvironment coupled with overexpression of pathway constituents in response to LPA1 inhibition.

**Discussion**

On the basis of the inverse expression and functional interaction of Nm23-H1 and LPA1 (26,27), we hypothesized that a LPA1 inhibitor could function as a metastasis suppressor. Debio-0719 statistically significantly inhibited the metastasis of 4T1 murine mammary cells to the lungs and liver in four different spontaneous metastasis experiments. In the MDA-MB-231 human breast carcinoma model, Debio-0719 statistically significantly inhibited the formation of pulmonary metastases. Mouse survival was dependent on continuous Debio-0719 administration. These data agree with previous reports using various LPA1 pathway inhibitors assessing aspects of metastasis (39,66). LPA1 knockdown also statistically significantly prevented metastasis formation in the 4T1 model system, indicating that the effect of Debio-0719 is largely LPA1 specific and that the effects resulting from pharmacological inhibition of LPA1 can be recapitulated by knocking down LPA1.

LPA1 inhibition did not statistically significantly reduce primary tumor size in any experiment we performed, suggesting that the LPA1 pathway has no major role in tumor initiation and maintenance at the primary site in our model systems. Thus, LPA1 inhibition has the properties of a metastasis suppressor (2,5,67). The Debio-0719 compound was nontoxic in our experiments, indicating that LPA1 can be targeted with a good safety margin; currently, various compounds directed at this pathway are under development (68). Previous reports have similarly demonstrated distinct responses in primary and metastatic sites to changes in tumor cell gene expression or drugs (69–71). Because virtually all cancer therapeutics currently in use were validated by short-term inhibition of subcutaneous tumor growth as a preclinical endpoint, the LPA1 inhibitor, Debio-0719, would have been missed by traditional validation strategies.

Our data also indicate that LPA1 pathway inhibition induced aspects of metastatic dormancy. Dormancy, the long-term persistence of subclinical solitary or micrometastatic tumor cells, is poorly understood, and it has been characterized as reflecting a balance of proliferation and apoptosis, cell cycle quiescence, immunological surveillance, or other mechanisms (72–79). In previous studies, when tested, dormant tumor cells were insensitive to traditional chemotherapeutics (80). A translational goal in breast cancer is to induce or sustain a chronic dormant phenotype in tumor cells. In our
Activation of p38 was a consistent indicator of dormancy in the 4T1 and MDA-MB-231T models studied. Selective activation of p38 in metastatic lesions may result from the multitude of cytokines present in the liver and lungs, many of which are known to induce p38 stress responses (82–97). We hypothesize that the LPA1 pathway serves as a gatekeeper for many of these cytokines to activate p38: Inhibition of LPA1, by Debio-0719 or shRNA targeting LPA1, resulted in the upregulation of components of the p38 stress kinase pathway at the protein level, including MKK3, MKK4, and MKKK1. Thus, signaling that activates p38 from a multitude of cytokines present in the metastatic microenvironments could be amplified by overexpression of pathway constituents. It is noteworthy that MKK4 is a validated metastasis suppressor gene (98); thus, one mode of action of a metastasis-suppressive compound may be the elevation of other suppressor proteins. To our knowledge, Debio-0719 is one of the first compounds to induce metastatic dormancy in triple negative breast cancer cells. As a monotherapy, this type of inhibitor would be likely to have minimal activity in the advanced metastatic setting of phase I trials, but it would be expected to be effective in the adjuvant setting, which is similar to the design of the preclinical experiments. Adjuvant setting trials are large and costly, and therefore they are unsuitable for validating potential metastasis-suppressive drugs such as Debio-0719. Rather, we propose that initial clinical testing use pre- and post-treatment tumor biopsies to determine the effect of drug on Ki67, Erk, and phospho-p38 levels; phase II efficacy trials could enroll high-risk patients to determine relapse-free survival.

Our study is not without limitations. Our experiments did not determine the duration of the dormancy response to LPA1 inhibition. Also, Debio-0719 should be tested in other model systems. Other LPA1-linked and -independent signaling pathways also likely mediate metastatic dormancy, and further studies are necessary to identify these pathways.

In summary, a new drug development paradigm is presented to induce tumor dormancy in metastatic sites. Inhibition of signaling by the ubiquitous serum phospholipid LPA through the LPA1 receptor resulted in tumor withdrawal from the cell cycle in metastatic niches and a statistically significant prevention of metastasis formation. With such inhibitors in hand, the interaction of dormancy pathways and standard of care therapeutics, radiation therapy, patient stress, and other important factors can be determined to develop a deeper picture of potential preventative and therapeutic scenarios.

References


Funding
Intramural program of the National Cancer Institute and Breast Cancer Research Stamp Fund awarded through competitive peer review by the National Cancer Institute (to PSS); ISCIII (ADE09/90041) and the Burdlinoa Professorship on Molecular Medicine (for FV-V).

Notes
The funders did not have a role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the article; and the decision to submit the article for publication. The authors thank Dr Gary Sahagian, Tufts University, for luciferase-labeled 4T1 cells. M. Barber and M. Murone are employees of Debiopharm S.A.

Affiliations of authors: The Women’s Cancers Section, Laboratory of Molecular Pharmacology (U-CAM, JWC, JCN, CEH, DP, PSS) and the Biostatistics and Data Management Section (DUL, SMS), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Institute of Applied Molecular Medicine, Laboratory Animal Science Program, National Cancer Institute, SAIC-Frederick, Frederick, MD (MA); CEU-San Pablo University School of Medicine and Hospital of Madrid Scientific Foundation, Urb. Moncéntrico, Boadilla del Monte, Madrid, Spain (FV-V); Debiopharm S.A., Lausanne, Switzerland (MB, MM); Bristol-Myers Squibb, Pennington, NJ (current affiliation for CEH); Center for Translational Research, Institute for Research and Innovation, Towson, MD (current affiliation for J-CAM).